RESUMO
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease involving apocrine gland-bearing regions. There is an under-representation of non-Caucasians in epidemiologic studies of HS. The characteristics of HS in Israeli Arabs have not yet been studied. OBJECTIVES: To investigate the demographic and clinical profile of HS in the Israeli Arab population. METHODS: A retrospective analysis was conducted in two cohorts of patients with HS in Israel. The patients were derived from the database of a large health management organization (n=4191, 639 Arabs; population-based) and a major tertiary medical center (n=372, 49 Arabs). Demographic and clinical data were compared between ethnic groups. RESULTS: The prevalence of HS in Israeli Arabs was found to be 0.5%, fivefold higher than in Jews. Arab patients were younger (35.3 vs. 40.5 years, P < 0.001) and mostly male (52% vs. 35.7%, P < 0.001), with lower rates of co-morbidities, including smoking (40.8% vs. 55.7%, P < 0.001), hyperlipidemia, and depression as well as a higher rate of dissecting cellulitis (10.2% vs. 1.9%, P = 0.008). HS was more severe in Arabs, but of shorter duration, with mainly axillary involvement (79.6% vs. 57.9%, P = 0.004). Treatment with hormones was more common in Jews, and with biologic agents in Arabs. CONCLUSIONS: The findings suggest a different phenotype of HS in Arabs, warranting further study.
Assuntos
Árabes , Hidradenite Supurativa , Judeus , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Árabes/estatística & dados numéricos , Estudos de Coortes , Comorbidade , Hidradenite Supurativa/etnologia , Hidradenite Supurativa/epidemiologia , Israel/epidemiologia , Judeus/estatística & dados numéricos , Prevalência , Estudos RetrospectivosRESUMO
BACKGROUND: Hidradenitis suppurativa (HS) is an inflammatory skin disorder characterized by recurring painful and suppurating lesions, with the disease disproportionately affecting black populations in the United States. Ethnoracial representation in clinical trials is vital to ensuring results are generalizable. The purpose of this study is to examine whether ethnic or racial disparities exist in HS clinical trials. METHODS: The US National Library of Medicine clinical trials database (clinicaltrials.gov) was queried to identify HS clinical trials. Trials that did not present ethnic or racial data on either the website or publication were not considered. RESULTS: A total of 57 HS trials were identified. Of these, 23 trials, containing 2530 patients, included racial or ethnic data (Table 1). White patients made up 76.1% (1435/1886) of the study population, followed by Blacks or African Americans (13.7% (238/1732)), Hispanics or Latinos (7.2% (20/279), Asians (2.6% (26/1016)), American Indians or Alaska Natives (1.3% (14/1051)), and Native Hawaiians or Other Pacific Islanders (0.4% (4/926)). DISCUSSION: Our results establish a significant lack of minority ethnoracial representation in HS clinical trials. Since HS prevalence is highest among Blacks or African Americans, it is imperative that future clinical trials are conducted with a larger proportion of this population. Furthermore, clinical trials that did not report racial or ethnic information were conducted in countries with predominantly White populations, which likely skewed the results of this study and caused underreporting of these patients.
Assuntos
Ensaios Clínicos como Assunto , Etnicidade , Hidradenite Supurativa , Humanos , Negro ou Afro-Americano , Hidradenite Supurativa/etnologia , Hidradenite Supurativa/terapia , Hispânico ou Latino , Grupos Raciais , Estados Unidos , Brancos , Asiático , Indígena Americano ou Nativo do Alasca , Havaiano Nativo ou Outro Ilhéu do PacíficoRESUMO
BACKGROUND: Hidradenitis suppurativa disproportionately affects women, minorities, and skin of color. Botulinum toxin is a potential therapy; however, literature regarding its utility is sparse. OBJECTIVE: We analyzed evidence surrounding botulinum toxin in the treatment of hidradenitis suppurativa. METHODS: We conducted a database search of PubMed, Embase, and Cochrane library for studies addressing botulinum toxin therapy for hidradenitis suppurativa through June 10, 2020. Review articles, meta-analyses, and studies without published results were excluded. RESULTS: Seven studies met criteria for inclusion and review. Botulinum toxin administration resulted in either clinical improvement or improved quality of life in 96.8% (n = 30/31) of patients. Level of evidence was moderate. LIMITATIONS: Results are limited by the quantity and evidence level of reviewed studies. CONCLUSION: Botulinum toxin is a safe and potentially effective alternative for hidradenitis suppurativa patients resistant to standard of care therapies. Dermatologists can address this health disparity by strengthening recommendations with high-quality investigations regarding its therapeutic potential. J Drugs Dermatol. 2022;21(4):408-412. doi:10.36849/JDD.5747.
Assuntos
Toxinas Botulínicas , Hidradenite Supurativa , Feminino , Humanos , Toxinas Botulínicas/efeitos adversos , Hidradenite Supurativa/diagnóstico , Hidradenite Supurativa/tratamento farmacológico , Hidradenite Supurativa/etnologia , Qualidade de Vida , PeleAssuntos
Hidradenite Supurativa , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Analgésicos Opioides/uso terapêutico , Índice de Massa Corporal , California/epidemiologia , Criança , Feminino , Hidradenite Supurativa/complicações , Hidradenite Supurativa/tratamento farmacológico , Hidradenite Supurativa/etnologia , Humanos , Doenças Inflamatórias Intestinais/complicações , Doenças Inflamatórias Intestinais/epidemiologia , Masculino , Pessoa de Meia-Idade , Prevalência , Estudos Retrospectivos , Distribuição por Sexo , Fumar/etnologia , Atenção Terciária à Saúde , Adulto JovemRESUMO
BACKGROUND: Hidradenitis suppurativa (HS) is an often-debilitating disease characterized by chronic and recurrent painful nodules, abscesses, and sinus tracts affecting the intertriginous areas. Despite evidence in the literature of varying prevalence of HS among different racial and ethnic groups, no studies have evaluated the overall generalizability of clinical trial results considering the increased prevalence of HS among African American populations. Additionally, there is a paucity of data exploring the distribution of race and ethnicity in randomized controlled trials (RCTs) for HS. The goal of this analysis is to explore the distribution of race and ethnicity in recent HS RCTs. SUMMARY: Using ClinicalTrials.gov and PubMed, race and ethnicity demographics were extracted from phase II and III trials published from 2000 to August 2019. Fifteen trials were included and among these trials 669 (68.0%) participants were Caucasian and 138 (14.0%) were of African descent. Asians, American Indian or Alaskan Natives, and Native Hawaiian or other Pacific Islanders comprised 29 (2.9%), 3 (0.3%), and 1 (0.1%) participant respectively. Only 15 participants were reported as Hispanic as only three trials reported ethnicity data. The remaining 144 (14.6%) participants were recorded as "other/unspecified" (36 self-identified, 108 lacked race reporting). None of the trials included sub-analysis of treatment efficacy based on race or ethnicity.
Assuntos
Etnicidade/estatística & dados numéricos , Hidradenite Supurativa/etnologia , Hidradenite Supurativa/terapia , Seleção de Pacientes , População Branca/estatística & dados numéricos , Ensaios Clínicos como Assunto , HumanosRESUMO
The 14 authors of the first review article on hidradenitis suppurativa (HS) pathogenesis published 2008 in EXPERIMENTAL DERMATOLOGY cumulating from the 1st International Hidradenitis Suppurativa Research Symposium held March 30-April 2, 2006 in Dessau, Germany with 33 participants were prophetic when they wrote "Hopefully, this heralds a welcome new tradition: to get to the molecular heart of HS pathogenesis, which can only be achieved by a renaissance of solid basic HS research, as the key to developing more effective HS therapy." (Kurzen et al. What causes hidradenitis suppurativa? Exp Dermatol 2008;17:455). Fifteen years later, there is no doubt that the desired renaissance of solid basic HS research is progressing with rapid steps and that HS has developed deep roots among inflammatory diseases in Dermatology and beyond, recognized as "the only inflammatory skin disease than can be healed". This anniversary article of 43 research-performing authors from all around the globe in the official journal of the European Hidradenitis Suppurativa Foundation e.V. (EHSF e.V.) and the Hidradenitis Suppurativa Foundation, Inc (HSF USA) summarizes the evidence of the intense HS clinical and experimental research during the last 15 years in all aspects of the disease and provides information of the developments to come in the near future.
Assuntos
Hidradenite Supurativa/etiologia , Autoimunidade , Linfócitos B , Infecções Bacterianas/complicações , Complemento C5a/metabolismo , Citocinas/metabolismo , Genótipo , Hidradenite Supurativa/tratamento farmacológico , Hidradenite Supurativa/etnologia , Hidradenite Supurativa/metabolismo , Humanos , Mutação , Dor/etiologia , Fenótipo , Prurido/etiologia , Fatores de Risco , Pele/microbiologia , Fumar/efeitos adversos , Linfócitos T , TranscriptomaRESUMO
BACKGROUND: The association of adalimumab therapy with malignancy and infection is established in other inflammatory diseases; however, rates of hidradenitis suppurativa (HS) are based on case reports or retrospective healthcare data and the effect of adalimumab therapy on these rates is unknown. Previously reported rates in the PIONEER OLE Phase 3 study reported on rates only in a subpopulation of 88 participants rather than the entire cohort. AIM: To quantify rates of malignancy and serious infection in all patients with HS treated with adalimumab 40 mg weekly. METHODS: Reanalysis was undertaken of individual patient data from the PIONEER 1, PIONEER 2 and PIONEER open-label extension Phase 3 trial data encompassing 591 unique patients with HS administered adalimumab 40 mg weekly without concurrent antibiotic exposure. Incidence rates of serious infection and malignancy were calculated. RESULTS: Incidence rates of serious infection and malignancy were 2.14 and 0.46 per 100 patient-years, respectively. Rates of infection and malignancy were comparable to those in other inflammatory conditions examined. CONCLUSION: Incidence of serious infection in patients with HS on adalimumab is comparable to those with psoriasis and inflammatory arthropathies, but the incidence of malignancy is increased. This may reflect disease-specific malignancy risk rather than an effect of adalimumab.
Assuntos
Adalimumab/efeitos adversos , Suscetibilidade a Doenças/induzido quimicamente , Hidradenite Supurativa/tratamento farmacológico , Infecções/epidemiologia , Neoplasias/epidemiologia , Adalimumab/administração & dosagem , Adalimumab/uso terapêutico , Adulto , Estudos de Casos e Controles , Ensaios Clínicos como Assunto , Feminino , Hidradenite Supurativa/complicações , Hidradenite Supurativa/etnologia , Humanos , Incidência , Infecções/etiologia , Artropatias/complicações , Artropatias/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Neoplasias/etiologia , Psoríase/complicações , Psoríase/tratamento farmacológico , Estudos Retrospectivos , Inibidores do Fator de Necrose Tumoral/administração & dosagem , Inibidores do Fator de Necrose Tumoral/efeitos adversos , Inibidores do Fator de Necrose Tumoral/uso terapêuticoRESUMO
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that severely impairs patients' quality of life (QoL). Instruments such as the 10-item Dermatology Life Quality Index and 16-item Skindex-16 have been used to assess QoL in HS; however, it is unknown whether the shorter 3-item Skindex-mini can also provide an accurate assessment of skin-related QoL in patients with HS. OBJECTIVES: The aim was to assess how well the Skindex-16 correlates with its shorter adaptation, the Skindex-mini, in capturing QoL among patients with HS. METHODS: This retrospective cross-sectional study included all HS patients seen in the HS Clinic at The Emory Clinic between January 1, 2019, and August 16, 2019. We compared the correlation between the symptom, emotion, and function domains of the Skindex-16 and Skindex-mini using Pearson correlation coefficients (CC). Secondary outcome measures included individual survey item analysis, ItchyQuant scores, and numeric rating scale of pain. RESULTS: We identified 108 encounters among 75 unique hidradenitis suppurativa patients (43 black/African American, 18 white, 5 Asian/Pacific Islander, 3 Latino, 4 Other, 2 unknown). Pearson CC between the Skindex-16 and Skindex-mini domain scores for all encounters were 0.770 (P < .001), 0.787 (P < .001), and 0.801 (P < .001) for the symptom, emotion, and function domains, respectively. The mean pain and ItchyQuant scores were 4.14 (SD 3.31) and 3.55 (SD 3.34), respectively. CONCLUSIONS: The Skindex-mini correlated highly with the Skindex-16 in a racially diverse group of patients with HS. The Skindex-mini is a streamlined QoL instrument that could be practically implemented into routine clinical care among diverse patients presenting to dermatology.
Assuntos
Hidradenite Supurativa/etnologia , Hidradenite Supurativa/psicologia , Qualidade de Vida , Adulto , Feminino , Humanos , Masculino , Estudos Retrospectivos , Índice de Gravidade de DoençaRESUMO
Hidradenitis suppurativa (HS) is a chronic-relapsing and debilitating disease, which affects the components of the folliculopilosebaceous unit and severely impacts on the perceived health-related quality of life. Among the possible treatments, dietary interventions, such as fasting, have been described to positively impact on HS. However, nothing is known about the effects of circadian, intermittent fasting, such as the Ramadan fasting. A sample of 55 HS patients (24 males (43.6%) and 31 females (56.4%), mean age 39.65 ± 8.39 years, average disease duration 14.31 ± 7.03 years) was recruited in the present study. The "Severity of International Hidradenitis Suppurativa Severity Score System" (IHS4) decreased significantly from 11.00 ± 5.88 (before Ramadan) to 10.15 ± 6.45 (after Ramadan), with a mean difference of -0.85 ± 0.83 (p < 0.0001). At the univariate analyses, the improvement was associated with HS phenotype (with a prominent improvement among those with ectopic type), treatment (with the improvement being higher in patients receiving topical and systemic antibiotics compared to those treated with biologics), the "Autoinflammatory Disease Damage Index" (ADDI), and Hurley scores. At the multivariate regression analysis, only the Hurley score (regression coefficient = 0.70, p = 0.0003) was found to be an independent predictor of change in the IHS4 score after fasting. The improvement in the IHS4 score was not, however, associated with weight loss. In conclusion, the Ramadan fasting proved to be safe and effective in HS patients. Considering the small sample size and the exploratory nature of the present investigation, further studies in the field are warranted, especially longitudinal, prospective and randomized ones.
Assuntos
Ritmo Circadiano , Jejum , Comportamento Alimentar , Hidradenite Supurativa/dietoterapia , Islamismo , Adulto , Estudos Cross-Over , Europa (Continente)/epidemiologia , Jejum/efeitos adversos , Comportamento Alimentar/etnologia , Feminino , Hidradenite Supurativa/diagnóstico , Hidradenite Supurativa/etnologia , Hidradenite Supurativa/psicologia , Humanos , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Indução de Remissão , Estudos Retrospectivos , Índice de Gravidade de Doença , Fatores de Tempo , Resultado do Tratamento , Adulto JovemRESUMO
BACKGROUND: Evidence establishing a link between acne vulgaris (AV) and hidradenitis suppurativa (HS) is limited, and the burden of AV in adults with HS is unknown. OBJECTIVE: To determine the prevalence of AV among adults with HS and determine the strength of this association. METHODS: Cross-sectional analysis identifying adults with AV among patients with and without HS by using electronic health record data from a population-based sample of more than 55 million patients. RESULTS: The prevalence of AV among adults with HS was 15.2% (7315 of 48,085) compared with 2.9% (497,360 of 16,899,470) for adults without HS (P < .001). The prevalence was greatest among patients with HS who were female (5870 of 35,790 [16.4%]), were 18 to 44 years old (5260 of 28,870 [18.2%]), were nonwhite (3120 of 17,825 [17.5%]), were obese (5430 of 35,135 [15.5%]), and had polycystic ovarian syndrome (685 of 2385 [28.7%]). Patients with HS had 4.51 [95% confidence interval, 4.40-4.63] times the odds of having AV than did patients without HS, with the higher likelihood of having AV persisting across all subgroups of patients with HS. The association between HS and AV was generally stronger for patients who were male, and 65 years of age or older. LIMITATIONS: Influence of disease severity in HS, or in acne, on the strength of the association could not be assessed. CONCLUSION: Patients with HS may benefit from assessment of acne status and optimization of comanagement strategies.
Assuntos
Acne Vulgar/epidemiologia , Hidradenite Supurativa/epidemiologia , Acne Vulgar/etnologia , Adolescente , Adulto , Fatores Etários , Idoso , Comorbidade , Estudos Transversais , Feminino , Hidradenite Supurativa/etnologia , Humanos , Masculino , Pessoa de Meia-Idade , Obesidade/epidemiologia , Síndrome do Ovário Policístico/epidemiologia , Prevalência , Fatores de Risco , Fatores Sexuais , Estados Unidos/epidemiologia , Adulto JovemRESUMO
BACKGROUND: The relationship between tobacco use and hidradenitis suppurativa (HS) is controversial. OBJECTIVES: To determine the incidence of HS among tobacco smokers. METHODS: Retrospective cohort analysis identifying incident HS cases among adult tobacco smokers and nonsmokers sampled from a demographically heterogeneous population-based sample of over 50 million unique patients across all census regions in the U.S.A. RESULTS: We identified 3 924 310 tobacco smokers, which included 7860 patients newly diagnosed with HS. Tobacco smokers diagnosed with HS were most commonly aged 18-39 years (3795 of 7860; 48·3%), women (5640 of 7860; 71·8%), white (5200 of 7860; 66·2%) and those with body mass index (BMI) ≥ 30 (5690 of 7860; 72·4%). Overall incidence of HS was 0·20% (7860 of 3 924 310) among tobacco smokers and 0·11% (8430 of 8 027 790) among nonsmokers (P < 0·001). Incidence was greatest among tobacco smokers who were aged 30-39 years (0·35%), women (0·28%), African Americans (0·46%) and those with BMI ≥ 30 (0·33%). The overall adjusted odds of developing HS was 1·90 (95% confidence interval 1·84-1·96) among tobacco smokers, compared with nonsmokers (P < 0·001). HS incidence among tobacco smokers remained increased within each demographic subgroup. CONCLUSIONS: Incidence of HS appears to be doubled among tobacco smokers. These findings may support evidence-based counselling efforts for the cessation of smoking in populations at risk for HS.
Assuntos
Hidradenite Supurativa/epidemiologia , Fumar Tabaco/epidemiologia , Adolescente , Adulto , Negro ou Afro-Americano/etnologia , Idoso , Idoso de 80 Anos ou mais , Feminino , Hidradenite Supurativa/etnologia , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Fumar Tabaco/etnologia , Estados Unidos/epidemiologia , Adulto JovemRESUMO
Hidradenitis suppurativa (HS) is a chronic, inflammatory, debilitating disease of unknown etiology. HS can occur in people of all ethnicities and ages, and affects approximately 3-4% of the United States. To date, few studies have specifically examined the race prevalence of HS; further epidemiological research is needed to identify specific trends among HS and its racial predilections. At our center, 1.3% of African-American patients were seen for HS, compared to 18% of Caucasian patients (p<0.05), and the percent ratio of African-American versus Caucasian patients with HS was 7.22:1. Our number ratio of African-American patients versus Caucasian patients with HS was 1.19:1. Studies performed at Henry Ford Medical Center and University of Pittsburgh report ratios of 1.64:1 and 1.98:1 respectively. These data support study trends suggesting HS is more common among patients of African-American descent. A large, population-based study across the United States is needed to better assess the associations between ethnicity and HS. Examining this patient population has the potential to improve our understanding of HS pathophysiology, and will enable clinicians to better manage patients with this disease.
Assuntos
Negro ou Afro-Americano , Hidradenite Supurativa/etnologia , População Branca , Instituições de Assistência Ambulatorial , Humanos , Ohio/epidemiologia , Prevalência , Estudos RetrospectivosRESUMO
Importance: The true prevalence of hidradenitis suppurativa (HS) is unknown. Objective: To establish standardized overall and group-specific prevalence estimates for HS in the United States. Design, Setting, and Participants: This retrospective analysis included a demographically heterogeneous population-based sample of more than 48 million unique patients across all US census regions. As of October 27, 2016, a total of 47â¯690 patients with HS were identified using electronic health record data. Main Outcomes and Measures: Standardized overall point prevalence for HS and sex-, age-, and race-specific prevalence estimates of HS in the general US population. Results: Of the 47â¯690 patients with HS (26.2% men and 73.8% women), the overall HS prevalence in the US population sample was 0.10%, or 98 per 100â¯000 persons (95% CI, 97-99 per 100â¯000 persons). The adjusted prevalence in women was 137 per 100â¯000 (95% CI, 136-139 per 100â¯000), more than twice that of men (58 per 100â¯000; 95% CI, 57-59 per 100â¯000; P < .001). The prevalence of HS was highest among patients aged 30 to 39 years (172 per 100â¯000; 95% CI, 169-275 per 100â¯000) compared with all other age groups (range, 15-150 per 100â¯000; P < .001). Adjusted HS prevalences among African American (296 per 100â¯000; 95% CI, 291-300 per 100â¯000) and biracial (218 per 100â¯000; 95% CI, 202-235 per 100â¯000) patients were more than 3-fold and 2-fold greater, respectively, than that among white patients (95 per 100â¯000; 95% CI, 94-96 per 100â¯000; P < .001). Conclusions and Relevance: Hidradenitis suppurativa is an uncommon, but not rare, disease in the United States that disproportionately affects female patients, young adults, and African American and biracial patients.
Assuntos
Negro ou Afro-Americano/estatística & dados numéricos , Hidradenite Supurativa/epidemiologia , Grupos Raciais/estatística & dados numéricos , População Branca/estatística & dados numéricos , Adolescente , Adulto , Distribuição por Idade , Criança , Pré-Escolar , Estudos de Coortes , Feminino , Hidradenite Supurativa/etnologia , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Prevalência , Estudos Retrospectivos , Distribuição por Sexo , Estados Unidos/epidemiologia , Adulto JovemRESUMO
Hidradenitis suppurativa (HS) is a chronic cutaneous inflammatory disease. Few reports have been published on the influence of race, ethnicity, and other patient demographic factors as determinants of care for HS. Data from the 2005 to 2011 National Ambulatory Medical Care Survey (NAMCS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS) were analyzed for to assess factors that were predictive of outpatient visits for HS. Logistic regression controlling for demographic and other factors showed several disparities. African Americans are more likely to experience clinic visits for HS than Whites (Odds Ratio (OR) 2.00, p = 0.047). Moreover, non-Hispanic, non-Latino patients are more likely to visit the clinic for HS than Hispanic, Latino patients (OR 5.49, p = 0.002). Additionally, with increasing patient age, there is less likelihood of a clinic visit for HS (OR 0.99; p = 0.03). Although obese patients were 3.5 times more likely to have an HS office visit than normal weight individuals, this difference was not significant (p = 0.07). Since weight was not collected in this survey until 2005 and data collection continues, further years of data may refine these estimates. These results suggest there may be either increased risk of HS among specific groups, disparities in health access for care of HS, or both.
Assuntos
Acessibilidade aos Serviços de Saúde/estatística & dados numéricos , Disparidades em Assistência à Saúde/etnologia , Hidradenite Supurativa , Obesidade/epidemiologia , Adulto , Negro ou Afro-Americano/estatística & dados numéricos , Assistência Ambulatorial/estatística & dados numéricos , Demografia , Feminino , Pesquisas sobre Atenção à Saúde/estatística & dados numéricos , Hidradenite Supurativa/diagnóstico , Hidradenite Supurativa/etnologia , Hispânico ou Latino/estatística & dados numéricos , Humanos , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Estados Unidos/epidemiologia , População Branca/estatística & dados numéricosRESUMO
Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease. Although most studies on HS are conducted in largely Caucasian populations, evidence demonstrates a higher prevalence in patients with skin of color, including African and Hispanic populations. These racial subgroups are likely at risk for greater disease burden due to a higher prevalence of components of the metabolic syndrome, comorbid depression, and low socioeconomic status; however, there is a paucity of research in these populations. Additionally, studies examining the genetic and anatomical basis for HS, as well as the response to HS therapies, are lacking for patients with skin of color. Complicating this issue is the limited access to effective medical care, including dermatologists, for African and Hispanic populations as well as other minority groups. In this review, we identify gaps in the knowledge base, highlight the association between HS and patients with skin of color, and provide direction for much needed research into this condition.
Assuntos
População Negra , Hidradenite Supurativa/etnologia , Hidradenite Supurativa/etiologia , População Branca , Depressão/etiologia , Acessibilidade aos Serviços de Saúde , Hidradenite Supurativa/tratamento farmacológico , Hidradenite Supurativa/psicologia , Humanos , Síndrome Metabólica/etnologia , Qualidade de Vida , Fatores de Risco , Classe SocialRESUMO
Hidradenitis suppurativa (HS) is characterized by chronic inflammation, recurrent abscesses, and scarring. Surgery is performed when medical management and antibiotic therapy fails. This study sought to evaluate the demographics, surgical procedures, bacteriology, pharmacologic intervention, and quality of life of patients with recalcitrant HS requiring surgical intervention. A retrospective chart review was performed of 76 recalcitrant HS patients at the University of Illinois Medical Center. Patient demographics, bacterial culture, and surgery data were reviewed. Quality of life was assessed using the 36-item short-form health survey. Patients were mostly female (73.7%) and African American (81.6%) with a mean duration of symptoms of 8.6 years before surgery. Patients underwent at least one surgical procedure, most often to the axillae (57.6%) and 73.7 per cent received antibiotics. The most common culture isolates were Corynebacterium species (14.0%), Staphylococcus epidermidis (13.1%), and Staphylococcus aureus (10.4%) with varying resistance patterns. Surveyed patients had depressed 36-item short-form health survey physical functioning and social functioning scores. Recalcitrant HS patients with progressive symptomology over approximately nine years before surgical intervention were more likely to be African American women with axillary HS. Quality of life was diminished. We recommend initial treatment of HS with clindamycin and trimethoprim-sulfamethoxazole in clindamycin refractory cases.